Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Fidrisertib succinate by Ipsen for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva): Likelihood of Approval
Fidrisertib succinate is under clinical development by Ipsen and currently in Phase II for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)....
Irinotecan hydrochloride by Ipsen for Gastric Cancer: Likelihood of Approval
Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...
Tazemetostat hydrobromide by Ipsen for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma): Likelihood of Approval
Tazemetostat hydrobromide is under clinical development by Ipsen and currently in Phase II for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma). According...
Tazemetostat hydrobromide by Ipsen for Chordoma: Likelihood of Approval
Tazemetostat hydrobromide is under clinical development by Ipsen and currently in Phase II for Chordoma. According to GlobalData, Phase II...
Tazemetostat hydrobromide by Ipsen for Chondrosarcoma: Likelihood of Approval
Tazemetostat hydrobromide is under clinical development by Ipsen and currently in Phase II for Chondrosarcoma. According to GlobalData, Phase II...
Irinotecan hydrochloride by Ipsen for Solid Tumor: Likelihood of Approval
Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Cabozantinib s-malate by Ipsen for Adrenocortical Carcinoma (Adrenal Cortex Cancer): Likelihood of Approval
Cabozantinib s-malate is under clinical development by Ipsen and currently in Phase II for Adrenocortical Carcinoma (Adrenal Cortex Cancer). According...
Cabozantinib s-malate by Ipsen for Neuroendocrine Cancer: Likelihood of Approval
Cabozantinib s-malate is under clinical development by Ipsen and currently in Phase II for Neuroendocrine Cancer. According to GlobalData, Phase...
Irinotecan hydrochloride by Ipsen for Epithelial Ovarian Cancer: Likelihood of Approval
Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData,...
Ritivixibat by Ipsen for Primary Sclerosing Cholangitis: Likelihood of Approval
Ritivixibat is under clinical development by Ipsen and currently in Phase II for Primary Sclerosing Cholangitis. According to GlobalData, Phase...
Irinotecan hydrochloride by Ipsen for Epithelial Ovarian Cancer: Likelihood of Approval
Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData,...
IPN-01194 by Ipsen for Metastatic Colorectal Cancer: Likelihood of Approval
IPN-01194 is under clinical development by Ipsen and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
IPN-01194 by Ipsen for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
IPN-01194 is under clinical development by Ipsen and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC)....
IPN-01194 by Ipsen for Solid Tumor: Likelihood of Approval
IPN-01194 is under clinical development by Ipsen and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
IPN-01194 by Ipsen for Metastatic Melanoma: Likelihood of Approval
IPN-01194 is under clinical development by Ipsen and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...
IPN-01194 by Ipsen for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
IPN-01194 is under clinical development by Ipsen and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
Irinotecan hydrochloride by Ipsen for Neuroendocrine Carcinoma: Likelihood of Approval
Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase II for Neuroendocrine Carcinoma. According to GlobalData, Phase...
Odevixibat by Ipsen for Biliary Atresia: Likelihood of Approval
Odevixibat is under clinical development by Ipsen and currently in Phase III for Biliary Atresia. According to GlobalData, Phase III...
IPN-60250 by Ipsen for Liver Diseases: Likelihood of Approval
IPN-60250 is under clinical development by Ipsen and currently in Phase I for Liver Diseases. According to GlobalData, Phase I...
IPN-60250 by Ipsen for Primary Biliary Cholangitis (Primary Biliary Cirrhosis): Likelihood of Approval
IPN-60250 is under clinical development by Ipsen and currently in Phase I for Primary Biliary Cholangitis (Primary Biliary Cirrhosis). According...